

PRIOR AUTHORIZATION POLICY

POLICY: Cystic Fibrosis – Orkambi Prior Authorization Policy

- Orkambi® (lumacaftor/ivacaftor tablets and oral granules – Vertex)

REVIEW DATE: 07/06/2022; selected revision 09/07/2022

OVERVIEW

Orkambi, a combination of lumacaftor and ivacaftor, is indicated for the treatment of **cystic fibrosis** in patients ≥ 1 year of age who are homozygous for the F508del mutation in the cystic fibrosis transmembrane regulator (CFTR) gene.¹

If the patient's genotype is unknown, an FDA-cleared cystic fibrosis mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. The efficacy and safety of Orkambi have not been established in patients with cystic fibrosis other than those homozygous for the F508del mutation. Orkambi contains a unique chemical entity, lumacaftor, which is a CFTR corrector that increases trafficking of F508del CFTR to the cell surface, and ivacaftor (the same active ingredient contained in Kalydeco® [ivacaftor tablets and oral granules]), a CFTR potentiator that enhances chloride transport of CFTR on the cell surface. The F508del mutation in CFTR causes cystic fibrosis by limiting the amount of CFTR protein that reaches the epithelial cell surface.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Orkambi. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Orkambi as well as the monitoring required for adverse events and long-term efficacy, approval requires Orkambi to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Orkambi is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Cystic Fibrosis, Homozygous for the F508del (Phe508del) Mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) Gene.** Approve for 1 year if the patient meets all of the following criteria (A, B, and C):
 - A) Patient is ≥ 1 year of age; AND
 - B) Patient is homozygous for the F508del (Phe508del) mutation in the CFTR gene (meaning the patient has two copies of the F508del [Phe508del] mutation); AND
 - C) The medication is prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Orkambi is not recommended in the following situations:

07/06/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

1. **Cystic Fibrosis, Heterozygous for the F508del (Phe508del) Mutation in the CFTR Gene.** Orkambi is not indicated for patients with only one copy of the F508del mutation in the CFTR gene.¹
2. **Combination Therapy with Kalydeco (ivacaftor tablets and oral granules), Symdeko (tezacaftor/ivacaftor; ivacaftor tablets, co-packaged), or Trikafta (elxacaftor/tezacaftor/ivacaftor tablets; ivacaftor tablets, co-packaged).** Orkambi contains ivacaftor, the active agent in Kalydeco and therefore is not indicated in combination with Kalydeco. Symdeko and Trikafta contain ivacaftor and are therefore not indicated in combination with Orkambi.
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Orkambi[®] tablets and oral granules [prescribing information]. Cambridge, MA: Vertex; September 2022.